Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[No title available]
[No authors listed] [No authors listed] PMID: 28976850
Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine.
Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, White S, Khan AS, Racine T, Choi H, Boyer J, Park YK, Trottier S, Remigio C, Krieger D, Spruill SE, Bagarazzi M, Kobinger GP, Weiner DB, Maslow JN. Tebas P, et al. Among authors: spruill se. N Engl J Med. 2021 Sep 16;385(12):e35. doi: 10.1056/NEJMoa1708120. N Engl J Med. 2021. PMID: 34525286 Free PMC article. Clinical Trial.
Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device.
Kim WJ, Roberts CC, Song JY, Yoon JG, Seong H, Hyun HJ, Lee H, Gil A, Oh Y, Park JE, Jeon B, Lee JE, Choi SK, Yoon SK, Lee S, Kim B, Kane D, Spruill S, Kudchodkar SB, Muthumani K, Park YK, Kwon I, Jeong M, Maslow JN. Kim WJ, et al. Among authors: spruill s. Int J Infect Dis. 2023 Mar;128:112-120. doi: 10.1016/j.ijid.2022.12.037. Epub 2022 Dec 31. Int J Infect Dis. 2023. PMID: 36592685 Free PMC article.
Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.
Kim WJ, Roberts CC, Song JY, Yoon JG, Seong H, Hyun HJ, Lee H, Gil A, Oh Y, Park JE, Lee JE, Jeon B, Kane D, Spruill S, Kudchodkar SB, Muthumani K, Park YK, Kwon I, Maslow JN. Kim WJ, et al. Among authors: spruill s. Vaccine. 2023 Jun 29;41(29):4206-4211. doi: 10.1016/j.vaccine.2023.06.013. Epub 2023 Jun 6. Vaccine. 2023. PMID: 37296017 Free PMC article. Clinical Trial.
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J, Shune L, Joffe E, Young P, Spruill S, Katkov A, McRae R, Royston I, Faller DV, Rojkjaer L, Porcu P. Haverkos B, et al. Among authors: spruill s. Blood Adv. 2023 Oct 24;7(20):6339-6350. doi: 10.1182/bloodadvances.2023010330. Blood Adv. 2023. PMID: 37530631 Free PMC article. Clinical Trial.
Increasing oat β-glucan viscosity in a breakfast meal slows gastric emptying and reduces glycemic and insulinemic responses but has no effect on appetite, food intake, or plasma ghrelin and PYY responses in healthy humans: a randomized, placebo-controlled, crossover trial.
Wolever TMS, Tosh SM, Spruill SE, Jenkins AL, Ezatagha A, Duss R, Johnson J, Chu Y, Steinert RE. Wolever TMS, et al. Among authors: spruill se. Am J Clin Nutr. 2020 Feb 1;111(2):319-328. doi: 10.1093/ajcn/nqz285. Am J Clin Nutr. 2020. PMID: 31828287 Free article. Clinical Trial.
23 results